![]() |
JOURNAL TOOLS |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Cite this article as |

YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS PET AND GYNECOLOGICAL TUMORS
The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2):139-53
Copyright © 2016 EDIZIONI MINERVA MEDICA
language: English
New radiotracers in gynecological cancer: beyond 18F-FDG
Amarnath CHALLAPALLI ✉
Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK
Imaging plays an important role in the management of gynecological cancers. There is a clinical need for noninvasive prognostic biomarkers to provide more detailed tumor characterization at the baseline and/or early during therapy, which may potentially improve outcomes and enable a personalized treatment approach. Imaging parameters derived from PET/CT techniques are emerging as promising imaging biomarkers. This review details the current evidence and future potential of functional imaging using non-2-deoxy-2-[18F]fluoro-D-glucose (FDG) tracers in gynecological cancers.